CELYNTRA THERAPEUTICS
ActiveSummary
The computed 12-month bankruptcy probability of CELYNTRA THERAPEUTICS is 3.2% (moderate). The 2025 annual accounts show negative equity (-€9.6m) and a net result of -€3.1m. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 5% of 6,172 sector peers (NACE 46, financial year 2025). The company has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
Source: KBO- Status
- Active since 19-11-2019 Normal situation
- Activity
- Wholesale of pharmaceutical and medical goods NACE 46460
- Joint committee
- 207 Paritair Comité voor de bedienden uit de scheikundige nijverheid · annual accounts 2025
- Establishment unit
- 2.299.080.043 1435 Mont-Saint-Guibert, since 19-11-2019
- Financial year end
- 31 December
- Peppol
- Reachable since 27-11-2025
Board and ownership
- Jason ConnerDirector · since 05-03-2026
- Auditor
- PwCReviseurs d'Entreprises SRL
- Ncardia Holding0%· score 862025 annual accounts of Ncardia Holding
Financial position
- Bankruptcy probabilitywithin 12 months
- 3.2%
- Gross margin
- €560,992
- Turnover
- ≈ €2.8m
- estimated
- Loss
- €3.1m
- ▼ 52.1%
- Equity
- -€9.6m
- ▼ 40.1%
- Total assets
- €8.2m
- ▲ 3.4%
- Employees on 31-12-2025
- 13
- ▲ 8.3%
- Negative equity on 31-12-2025
Score breakdownraises riskNegative equity -€9.6mLoss of €3.1m, the second in a row (financial year 2025)Liquidity: current ratio 0.13, cash €445,0461 of the last 3 accounts lateShow the evidence
Checked score
About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small). It does better than 1% of them on solvency, 6% on liquidity, 1% on profitability and 6% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 15 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
Key points
- Risk: Negative equitydebts exceed assets in financial year 2025 -€9.6m View
- Risk: 7 loss-making years in a rowloss in financial year 2025 -€3.1m View
- Caution: Lower solvency than 95% of companies in wholesale tradesector median 45.2% · 6,172 companies -117.1% View
- Caution: Board changedlatest change 07-05-2026 · 1 in office 1 joined · 1 left View
- Positive: Result rose in 2025from -€6.4m to -€3.1m ▲ 52.1% View
Recent changes
- · Gazette deed Reappointment: PwCReviseurs d'Entreprises SRL (statutory auditor)Permanent representative: M. Romain Seffer
- · Gazette deed Resignation: Gustavo Mahler (director)Appointment: Jason Conner (sole director)
- · Gazette deed Resignation: Stefan Braam (sole director)Appointment: Gustavo Mahler (sole director)
Comparable companies
These companies have the same main activity as CELYNTRA THERAPEUTICS: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €4.3m and €7.1m, founded between 2014 and 2021.
| Company | Total assets | Gross margin |
|---|---|---|
| CELYNTRA THERAPEUTICS Mont-Saint-Guibert | €8.2m | €0.6m |
| COSMEX Tubize | €5.2m | €1.1m |
| MOTION MEDICAL Sint-Genesius-Rode | €7.1m | €0.8m |
| DENTAL ADDICT Braine-l'Alleud | €5.1m | €0.9m |
| ISIS MEDICAL Braine-l'Alleud | €4.3m | €1.7m |
| OPHTALMO SURGICAL Oudenaarde | €4.6m | €0.8m |
| LifeScan Belgium Westerlo | €5.7m | €2.2m |
Key facts about CELYNTRA THERAPEUTICS
- What is the company number of CELYNTRA THERAPEUTICS?
- The company number of CELYNTRA THERAPEUTICS is 0737.829.015. The VAT number is the same number with BE in front: BE 0737.829.015.
- Where is CELYNTRA THERAPEUTICS based?
- The registered office is at Rue Edouard Belin 2, 1435 Mont-Saint-Guibert.Company details
- What does CELYNTRA THERAPEUTICS do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of CELYNTRA THERAPEUTICS?
- The legal form of CELYNTRA THERAPEUTICS is Public limited company (NV).
- When was CELYNTRA THERAPEUTICS founded?
- CELYNTRA THERAPEUTICS was founded on 19-11-2019.
- Is CELYNTRA THERAPEUTICS still active?
- Yes, CELYNTRA THERAPEUTICS is an active enterprise in the KBO register.
- How many employees does CELYNTRA THERAPEUTICS have?
- CELYNTRA THERAPEUTICS had an average of 12.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does CELYNTRA THERAPEUTICS fall under?
- In its 2025 annual accounts, CELYNTRA THERAPEUTICS states joint committee 207 (Paritair Comité voor de bedienden uit de scheikundige nijverheid).
- What is the turnover of CELYNTRA THERAPEUTICS?
- The turnover in financial year 2025 is ≈ €2.8m. This figure is estimated from the gross margin of €560,992 and 35 comparable companies (NACE 464). It probably lies between €1.9m and €4.0m.
- Is CELYNTRA THERAPEUTICS profitable?
- In financial year 2025, CELYNTRA THERAPEUTICS made a loss of €3.1m.
- Where can I find the annual accounts of CELYNTRA THERAPEUTICS?
- CELYNTRA THERAPEUTICS filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CELYNTRA THERAPEUTICS due?
- CELYNTRA THERAPEUTICS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.